Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib versus carboplatin + paclitaxel for malignant pleural effusion in advanced non-small cell lung cancer
ChiCTR-OCH-11001856Phase 4Completed
- Sponsor
- Union Hospital
- Start
- Oct 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of gefitinib, carboplatin and paclitaxel in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Union Hospital. Primary endpoints: Overall survival and Immunological effects. Started Oct 2011; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OCH-11001856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-11001856.